Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorDana-Farber Cancer Institute

About this trial

The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).

Eligibility criteria

Qualifiers

Newly diagnosed patients with stages III-IV ovarian or endometrial cancer

Receiving first-line carboplatin and paclitaxel chemotherapy after surgery

≥18 years, children under the age of 18 will be excluded due to rarity of disease

Physician's clearance to participate in moderate-vigorous intensity exercise

Disqualifiers

Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist

Participants with uncontrolled intercurrent illness, as determined by the treating oncologist

Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist

Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)

Trial design

Treatments tested in this trial

  • Exercise
  • Attention Control

Treatment groups

30 Participants
are divided into 2 treatment groups

Sponsors and collaborators